ESMO 2021: NORSE Study
Highlights on erdafitinib in advanced urothelial cancer with FGFRa alterations: The NORSE study
Highlights on erdafitinib in advanced urothelial cancer with FGFRa alterations: The NORSE study
Treatment with avelumab combined with best supportive care following chemotherapy significantly extended overall survival compared…